학술논문
A Smoking Cessation Programme in HIV-Infected Individuals: A Pilot Study
Document Type
Article
Author
Battegay, M; Bernasconi, E; Böni, J; Bucher, H; Bürgisser, P; Cattacin, S; Cavassini, M; Dubs, R; Egger, M; Elzi, L; Erb, P; Fischer, M; Flepp, M; Fontana, A; Francioli, P; Furrer, H; Gorgievski, M; Günthard, H; Hirschel, B; Hösli, I; Kahlert, Ch; Kaiser, L; Karrer, U; Keiser, O; Kind, C; Klimkait, T; Ledergerber, B; Martinez, B; Müller, N; Nadal, D; Opravil, M; Paccaud, F; Pantaleo, G; Perrin, L; Bijker, J-C; Rickenbach, M; Rudin, C; Schmid, P; Schultze, D; Schüpbach, J; Speck, R; Taffé, P; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S; Elzi, Luigia; Spoerl, David; Voggensperger, Jacqueline; Nicca, Dunja; Simcock, Mathew; Bucher, Heiner C; Spirig, Rebecca; Battegay, Manuel
Source
Antiviral Therapy; August 2006, Vol. 11 Issue: 6 p787-796, 10p
Subject
Language
ISSN
13596535
Abstract
Background Antiretroviral therapy (ART) is a risk factor for cardiovascular disease (CVD) and smoking the most important modifiable cardiovascular risk factor.Methods We prospectively evaluated a smoking cessation programme (SCP) in HIV-infected individuals (intervention: counselling and nicotine replacement therapy). Primary endpoint was the smoking cessation rate at 12 months; secondary endpoints were CVD morbidity and mortality. Controls were a not randomized control group of smokers not participating in the SCP.Results Four-hundred and seventeen of 680 (61%) patients were smokers, and 34 of these participated in the SCP. Of these 34 individuals, 82% were male, the median age was 43 years, prior AIDS was recorded in 29%, and depressive disorder was recorded in 18%. Twenty-five (74%) patients were receiving ART. Additional risk factors were dyslipidaemia (68%), a prior cardiovascular event (24%), hypertension (15%), and a family history of CVD in 2/34 (6%) individuals. According to the Framingham equation, the 10-year risk of CVD was higher in SCP participants than in controls (11.2% versus 8.5%, P=0.06). At termination of the SCP, 17/34 (50%) individuals had stopped smoking compared with 57/383 (15%) controls. Self-reported smoking abstinence for =12 months was 13/34 (38%) in the intervention group and 27/383 (7%) in the control group (odds ration 6.2, 95% confidence interval 2.8–14.3). During the follow-up, two SCP participants and 4 controls experienced a myocardial infarction. One patient in the control group died of CVD.Conclusions SCP in HIV-infected individuals is feasible and should be encouraged. The long-term impact of smoking cessation on CVD morbidity and mortality should be evaluated in comparative trials.